Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2011 May;4(3):311-28. doi: 10.1586/ecp.11.11.

Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.

Author information

1
The Children's Hospital of Philadelphia, Science Center 3440 Market Street, Suite 200, Philadelphia, PA 19104, USA. elia@email.chop.edu

Abstract

The methylphenidate transdermal system (MTS) provides a novel method of delivery for methylphenidate, a well-studied and effective medication for attention-deficit/hyperactivity disorder. The MTS achieves two major goals. First, the delivery system allows for administration throughout the day with a single patch, thus improving adherence. Second, it is the first approved attention-deficit/hyperactivity disorder medication that is not administered orally, thus bypassing gastrointestinal absorption and first-pass metabolism through the enteric circulation. In this article, we review the current data on MTS, including preclinical, clinical and post-marketing studies, and compare efficacy and tolerability to currently available treatments.

PMID:
22114778
DOI:
10.1586/ecp.11.11
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center